Fig. 1 · Structure

Documents & Downloads

Brinzolamide

Cat. No. A11765 CAS 138890-62-7

Carbonic anhydrase inhibitor

Brinzolamide is a carbonic anhydrase inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
CAII 3.19 nM

Brinzolamide Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Brinzolamide from 3 published references. In vitro models include A549 cells. In vivo models include SD rats.

Brinzolamide In Vitro Studies

Brinzolamide was assessed in A549 cells using the neutral red cell viability assay, with solvent as control. The reported CC50 was 665.51 μM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Brinzolamide cell viability assessment

Cell-based study · A549 cells [1]

A549 cells were treated with Brinzolamide or solvent, and cell viability was measured using the neutral red assay. The reported CC50 was 665.51 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was measured by the neutral red assayCC50 CC50 = 665.51 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
72 h after treatment, cells were incubated for 3 h with neutral red dye
Method
treated with molecules or solvent
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Brinzolamide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > 7 Viability assays (S43, S45, S46); Table 2 legend (S275); Table 2 (T2.h2, T2.r2)

Cell viability was measured by the neutral red assay: Cell viability was measured by the neutral red assay; comparator: solvent — Materials and Methods > 7 Viability assays (S43); Table 2 (T2.h2, T2.r2)

Brinzolamide In Vivo Studies

In female mice with bead-injected eyes, daily Brinzolamide eye drops blunted but did not eliminate the cumulative intraocular pressure increase compared with bead injection alone. In SD rats, reduced-concentration Brinzolamide formulation Azopt administered to the right eye produced no observed ocular hypotensive effects. [2,3]

Brinzolamide and intraocular pressure following bead injection

Animal study · female C57BL/6 mice; bead-injected eyes [2]

Female C57BL/6 mice with bead-injected eyes received daily brinzolamide eye drops. Compared with bead injection alone, daily brinzolamide blunted but did not eliminate the cumulative IOP increase; mean daily IOP percentage increases were 20.0% ± 2.6% with brinzolamide and 26.9% ± 2.3% with bead injection alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mean daily IOP percentage increases (±SEM)mean daily IOP percentage increases 20.0% ± 2.6%[2]

Conditions shared by the study groups

Route
IOP-lowering eye drops
Treatment course
once per day for the duration of the experiment, including weekends; between 10 AM and 2 PM; 6-week study
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Brinzolamide brinzolamide 1%only bead injectionBoth agents blunted the cumulative IOP increase seen from bead injection, but neither eliminated it. mean daily IOP percentage increases (±SEM): only bead injection, 26.9% ± 2.3%; bead injection + daily brinzolamide, 20.0% ± 2.6%[2]
Brinzolamide brinzolamide 1%
Model: female C57BL/6 mice; bead-injected eyes
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Brinzolamide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1); Materials and Methods > Intraocular Pressure Elevation (S4, S6, S8, S9); Results (S60, S61, S63); Figure 2 legend (S102)

mean daily IOP percentage increases (±SEM): mean daily IOP percentage increases (±SEM); comparator: only bead injection — Results (S60, S61)

Brinzolamide brinzolamide 1% · Materials and Methods > Intraocular Pressure Elevation (S8, S9); Results (S60, S61); Figure 2 legend (S102)

Brinzolamide and intraocular pressure in SD rats

Animal study · SD rats (10–12 weeks) [3]

In SD rats, reduced-concentration Brinzolamide formulation Azopt was administered to the right eye, with saline as the control. No ocular hypotensive effects were observed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IOPReported result when the concentration of Azopt was reduced to one-fifth that of the original solution (i.e., 0.2%), no ocular hypotensive effects were observed[3]

Conditions shared by the study groups

Route
administrated to the right eye
Treatment course
The IOPs of both eyes were measured under anaesthesia every hour for up to 6 h.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Brinzolamide 0.2% Azopt (10 μL)saline (10 μL)when the concentration of Azopt was reduced to one-fifth that of the original solution (i.e., 0.2%), no ocular hypotensive effects were observed[3]
Brinzolamide 0.2% Azopt (10 μL)
Model: SD rats (10–12 weeks)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Brinzolamide; Compound label in the paper: Azopt

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Ocular hypotensive effects of brinzolamide prodrug nano eye-drops (S52); Methods > Evaluation of intraocular pressure (IOP) (S111, S112, S113, S114)

IOP: IOP; comparator: saline (10 μL) — Results > Ocular hypotensive effects of brinzolamide prodrug nano eye-drops (S52); Methods > Evaluation of intraocular pressure (IOP) (S112)

Brinzolamide 0.2% Azopt (10 μL) · Results > Ocular hypotensive effects of brinzolamide prodrug nano eye-drops (S52); Methods > Evaluation of intraocular pressure (IOP) (S113, S114)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 138890-62-7
Applications Carbonic anhydrase inhibitor
Formula C12H21N3O5S3
Molecular Weight 383.5
Synonyms Azopt
SMILES
CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 75 mg/mL (195.56 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Brinzolamide Research References

  1. [1] Josset L, Textoris J, Loriod B, et al. Gene expression signature-based screening identifies new broadly effective influenza a antivirals. PLoS One (2010). PMID: 20957181 DOI: 10.1371/journal.pone.0013169 Source material
  2. [2] van der Heijden ME, Shah P, Cowan CS, et al. Effects of Chronic and Acute Intraocular Pressure Elevation on Scotopic and Photopic Contrast Sensitivity in Mice. Invest Ophthalmol Vis Sci (2016). PMID: 27286365 DOI: 10.1167/iovs.16-19312 Source material
  3. [3] Ikuta Y, Aoyagi S, Tanaka Y, et al. Creation of nano eye-drops and effective drug delivery to the interior of the eye. Sci Rep (2017). PMID: 28290486 DOI: 10.1038/srep44229 Source material

Added to your cart

View Cart Checkout
Loading...